Mechanisms and pathogenicity of the PI3K pathway: from basic research to clinical application
DOI:
https://doi.org/10.54097/hset.v6i.974Keywords:
Enter key words or phrases in alphabetical order, separated by commas.Abstract
PI3K signaling pathway is one of the most important signaling pathways in tumorigenesis. Dysfunction of PI3K signalling pathway has been widely found in lymphatic hematologic tumors and solid tumors. Different PI3K inhibitors have shown anti-tumor activity against a variety of tumors. Furthermore, the FDA has approved various PI3K inhibitors for marketing or clinical studies, and have achieved considerable efficacy, especially in lymphoma and breast cancer. However, drug resistance and treatment-related adverse reactions remain unsolved. The PI3K signaling pathway also involves several other physiological functions related signaling pathway networks, and the combination therapy of selective inhibition of these signaling pathways needs to be further explored. New strategies include the combination of allosteric inhibitors and orthosteric inhibitors of PI3Kα and the development of inhibitors of salvage mutation sites. This review summarizes the clinical research progress and common drug resistance mechanisms of various common malignancies involved in PI3K inhibitors. In addition to targeting cancer cells, PI3K inhibitors also have great potential in cancer immunotherapy in the future.
Downloads
References
M. Whitman, D.R. Kaplan, B. Schaffhausen, et al., Association of phosphatidylinositol kinase activity with polyoma middle-t competent for transformation. Nature, 1985, pp. 239-242. DOI: https://dx.doi.org/10.1038/315239a0
L. Zhao and P.K. Vogt, Class i pi3k in oncogenic cellular transformation. Oncogene, 2008, pp. 5486-5496. DOI: https://dx.doi.org/10.1038/onc.2008.244
J. Bertacchini, N. Heidari, L. Mediani, et al., Targeting pi3k/akt/mtor network for treatment of leukemia. Cell Mol Life Sci, 2015, pp. 2337-2347. DOI: https://dx.doi.org/10.1007/s00018-015-1867-5
H.A. Blair, Duvelisib: First global approval. Drugs, 2018, pp. 1847-1853. DOI: https://dx.doi.org/10.1007/s40265-018-1013-4
R.D. Riehle, S. Cornea, and A. Degterev, Role of phosphatidylinositol 3,4,5-trisphosphate in cell signaling. Adv Exp Med Biol, 2013, pp. 105-139. DOI: https://dx.doi.org/10.1007/978-94-007-6331-9_7
M.D. Goncalves, B.D. Hopkins, and L.C. Cantley, Phosphatidylinositol 3-kinase, growth disorders, and cancer. N Engl J Med, 2018, pp. 2052-2062. DOI: https://dx.doi.org/10.1056/NEJMra1704560
B.T. Hennessy, D.L. Smith, P.T. Ram, et al., Exploiting the pi3k/akt pathway for cancer drug discovery. Nat Rev Drug Discov, 2005, pp. 988-1004. DOI: https://dx.doi.org/10.1038/nrd1902
J. Vallejo-Diaz, M. Chagoyen, M. Olazabal-Moran, et al., The opposing roles of pik3r1/p85alpha and pik3r2/p85beta in cancer. Trends Cancer, 2019, pp. 233-244. DOI: https://dx.doi.org/10.1016/j.trecan.2019.02.009
N.H. Fowler, F. Samaniego, W. Jurczak, et al., Umbralisib, a dual pi3kδ/ck1ε inhibitor in patients with relapsed or refractory indolent lymphoma. J Clin Oncol, 2021, pp. 1609-1618. DOI: https://dx.doi.org/10.1200/jco.20.03433
M.R. Fruman DA, Cantley LC., Phosphoinositide kinases. Annu Rev Biochem, 1998. DOI: https://dx.doi.org/10.1146/annurev.biochem.67.1.481
A.S. Alzahrani, Pi3k/akt/mtor inhibitors in cancer: At the bench and bedside. Semin Cancer Biol, 2019, pp. 125-132. DOI: https://dx.doi.org/10.1016/j.semcancer.2019.07.009
A. Brunet, A. Bonni, M.J. Zigmond, et al., Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell, 1999, pp. 857-868. DOI: https://dx.doi.org/10.1016/s0092-8674(00)80595-4
R.J. Shaw and L.C. Cantley, Ras, pi(3)k and mtor signalling controls tumour cell growth. Nature, 2006, pp. 424-430. DOI: https://dx.doi.org/10.1038/nature04869
Y. Furukawa-Hibi, Y. Kobayashi, C. Chen, et al., Foxo transcription factors in cell-cycle regulation and the response to oxidative stress. Antioxid Redox Signal, 2005, pp. 752-760. DOI: https://dx.doi.org/10.1089/ars.2005.7.752
S. Frame and P. Cohen, Gsk3 takes centre stage more than 20 years after its discovery. Biochem J, 2001, pp. 1-16. DOI: https://dx.doi.org/10.1042/0264-6021:3590001
H. Sun, R. Lesche, D.M. Li, et al., Pten modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and akt/protein kinase b signaling pathway. Proc Natl Acad Sci U S A, 1999, pp. 6199-6204. DOI: https://dx.doi.org/10.1073/pnas.96.11.6199
M.L. D Bonneau Mutations of the human pten gene. HUMAN MUTATION, 2000. DOI: https://dx.doi.org/ 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0
T. Gao, F. Furnari, and A.C. Newton, Phlpp: A phosphatase that directly dephosphorylates akt, promotes apoptosis, and suppresses tumor growth. Mol Cell, 2005, pp. 13-24. DOI: https://dx.doi.org/10.1016/j.molcel.2005.03.008
Y. Duan, J. Haybaeck, and Z. Yang, Therapeutic potential of pi3k/akt/mtor pathway in gastrointestinal stromal tumors: Rationale and progress. Cancers (Basel), 2020. DOI: https://dx.doi.org/10.3390/cancers12102972
D. Shome, J. Trent, L. Espandar, et al., Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine. Ophthalmology, 2008, pp. 483-487. DOI: https://dx.doi.org/10.1016/j.ophtha.2007.11.016
P. Schöffski, P. Reichardt, J.Y. Blay, et al., A phase i-ii study of everolimus (rad001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol, 2010, pp. 1990-1998. DOI: https://dx.doi.org/10.1093/annonc/mdq076
D. Mahadevan, E.G. Chiorean, W. Harris, et al., Phase i study of the multikinase prodrug sf1126 in solid tumors and b-cell malignancies. Journal of Clinical Oncology, 2011, pp. 3015-3015. DOI: https://dx.doi.org/10.1200/jco.2011.29.15_suppl.3015
S. Dolly, A.J. Wagner, J.C. Bendell, et al., A first-in-human, phase l study to evaluate the dual pi3k/mtor inhibitor gdc-0980 administered qd in patients with advanced solid tumors or non-hodgkin's lymphoma. Journal of Clinical Oncology, 2010, pp. 3079-3079. DOI: https://dx.doi.org/10.1200/jco.2010.28.15_suppl.3079
R. Mishra, H. Patel, S. Alanazi, et al., Pi3k inhibitors in cancer: Clinical implications and adverse effects. Int J Mol Sci, 2021. DOI: https://dx.doi.org/10.3390/ijms22073464
A. Papa, L. Wan, M. Bonora, et al., Cancer-associated pten mutants act in a dominant-negative manner to suppress pten protein function. Cell, 2014, pp. 595-610. DOI: https://dx.doi.org/10.1016/j.cell.2014.03.027
D. Juric, P. Castel, M. Griffith, et al., Convergent loss of pten leads to clinical resistance to a pi(3)kα inhibitor. Nature, 2015, pp. 240-244. DOI: https://dx.doi.org/10.1038/nature13948
W. Jiang, T. He, S. Liu, et al., The pik3ca e542k and e545k mutations promote glycolysis and proliferation via induction of the β-catenin/sirt3 signaling pathway in cervical cancer. J Hematol Oncol, 2018, pp. 139. DOI: https://dx.doi.org/10.1186/s13045-018-0674-5
A.B. Hanker, V. Kaklamani, and C.L. Arteaga, Challenges for the clinical development of pi3k inhibitors: Strategies to improve their impact in solid tumors. Cancer Discov, 2019, pp. 482-491. DOI: https://dx.doi.org/10.1158/2159-8290.Cd-18-1175
D. Juric, J. Rodon, J. Tabernero, et al., Phosphatidylinositol 3-kinase α-selective inhibition with alpelisib (byl719) in pik3ca-altered solid tumors: Results from the first-in-human study. J Clin Oncol, 2018, pp. 1291-1299. DOI: https://dx.doi.org/10.1200/jco.2017.72.7107
K.M. Ruicci, N. Pinto, M.I. Khan, et al., Erk-tsc2 signalling in constitutively-active hras mutant hnscc cells promotes resistance to pi3k inhibition. Oral Oncol, 2018, pp. 95-103. DOI: https://dx.doi.org/10.1016/j.oraloncology.2018.07.010
J.A. Engelman, L. Chen, X. Tan, et al., Effective use of pi3k and mek inhibitors to treat mutant kras g12d and pik3ca h1047r murine lung cancers. Nat Med, 2008, pp. 1351-1356. DOI: https://dx.doi.org/10.1038/nm.1890
H. Makinoshima, S. Umemura, A. Suzuki, et al., Metabolic determinants of sensitivity to phosphatidylinositol 3-kinase pathway inhibitor in small-cell lung carcinoma. Cancer Res, 2018, pp. 2179-2190. DOI: https://dx.doi.org/10.1158/0008-5472.Can-17-2109
M.W. Usman, J. Gao, T. Zheng, et al., Author correction: Macrophages confer resistance to pi3k inhibitor gdc-0941 in breast cancer through the activation of nf-κb signaling. Cell Death Dis, 2019, pp. 501. DOI: https://dx.doi.org/10.1038/s41419-019-1692-0
P. Xia and X.Y. Xu, Pi3k/akt/mtor signaling pathway in cancer stem cells: From basic research to clinical application. Am J Cancer Res, 2015, pp. 1602-1609.
F. André, E. Ciruelos, G. Rubovszky, et al., Alpelisib for pik3ca-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med, 2019, pp. 1929-1940. DOI: https://dx.doi.org/10.1056/NEJMoa1813904
F. André, E.M. Ciruelos, D. Juric, et al., Alpelisib plus fulvestrant for pik3ca-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: Final overall survival results from solar-1. Ann Oncol, 2021, pp. 208-217. DOI: https://dx.doi.org/10.1016/j.annonc.2020.11.011
W. Wu, J. Chen, H. Deng, et al., Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for er-positive, her2-negative breast cancer: A randomized pilot trial. BMC Cancer, 2021, pp. 862. DOI: https://dx.doi.org/10.1186/s12885-021-08612-y
J. Baselga, S.A. Im, H. Iwata, et al., Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, her2-negative, advanced breast cancer (belle-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 2017, pp. 904-916. DOI: https://dx.doi.org/10.1016/s1470-2045(17)30376-5
S. Ebrahimi, M. Hosseini, S. Shahidsales, et al., Targeting the akt/pi3k signaling pathway as a potential therapeutic strategy for the treatment of pancreatic cancer. 2017, pp. 1321-1331. DOI: https://dx.doi.org/10.2174/0929867324666170206142658
S. Jain, A.N. Shah, C.A. Santa-Maria, et al., Phase i study of alpelisib (byl-719) and trastuzumab emtansine (t-dm1) in her2-positive metastatic breast cancer (mbc) after trastuzumab and taxane therapy. Breast Cancer Res Treat, 2018, pp. 371-381. DOI: https://dx.doi.org/10.1007/s10549-018-4792-0
K.L. Reckamp, G. Giaccone, D.R. Camidge, et al., A phase 2 trial of dacomitinib (pf-00299804), an oral, irreversible pan-her (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer, 2014, pp. 1145-1154. DOI: https://dx.doi.org/10.1002/cncr.28561
M.J. Lee, N. Jin, J.R. Grandis, et al., Alterations and molecular targeting of the gsk-3 regulator, pi3k, in head and neck cancer. Biochim Biophys Acta Mol Cell Res, 2020, pp. 118679. DOI: https://dx.doi.org/10.1016/j.bbamcr.2020.118679
K. Patel and J.M. Pagel, Exploring a future for pi3k inhibitors in chronic lymphocytic leukemia. Curr Hematol Malig Rep, 2019, pp. 292-301. DOI: https://dx.doi.org/10.1007/s11899-019-00525-9
R.R. Furman, J.P. Sharman, S.E. Coutre, et al., Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med, 2014, pp. 997-1007. DOI: https://dx.doi.org/10.1056/NEJMoa1315226
Duvelisib, in Drugs and lactation database (lactmed). 2006, National Library of Medicine (US): Bethesda (MD).
I.W. Flinn, S. O'Brien, B. Kahl, et al., Duvelisib, a novel oral dual inhibitor of pi3k-δ,γ, is clinically active in advanced hematologic malignancies. Blood, 2018, pp. 877-887. DOI: https://dx.doi.org/10.1182/blood-2017-05-786566
A.K. Gopal, M.A. Fanale, C.H. Moskowitz, et al., Phase ii study of idelalisib, a selective inhibitor of pi3kδ, for relapsed/refractory classical hodgkin lymphoma. Ann Oncol, 2017, pp. 1057-1063. DOI: https://dx.doi.org/10.1093/annonc/mdx028
A.K. Gopal, B.S. Kahl, S. de Vos, et al., Pi3kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med, 2014, pp. 1008-1018. DOI: https://dx.doi.org/10.1056/NEJMoa1314583
C. Vernieri, F. Corti, F. Nichetti, et al., Everolimus versus alpelisib in advanced hormone receptor-positive her2-negative breast cancer: Targeting different nodes of the pi3k/akt/mtorc1 pathway with different clinical implications. Breast Cancer Res, 2020, pp. 33. DOI: https://dx.doi.org/10.1186/s13058-020-01271-0
P. Ghia, A. Pluta, M. Wach, et al., Ascend: Phase iii, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol, 2020, pp. 2849-2861. DOI: https://dx.doi.org/10.1200/jco.19.03355
S.M. Horwitz, R. Koch, P. Porcu, et al., Activity of the pi3k-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of t-cell lymphoma. Blood, 2018, pp. 888-898. DOI: https://dx.doi.org/10.1182/blood-2017-08-802470
A. Kumar, R. Bhatia, P. Chawla, et al., Copanlisib: Novel pi3k inhibitor for the treatment of lymphoma. Anticancer Agents Med Chem, 2020, pp. 1158-1172. DOI: https://dx.doi.org/10.2174/1871520620666200317105207
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
